课题基金 / 基金详情

NOVEL RECOMBINANT ADENOVIRUS VACCINE VECTORS FOR HIV/SIV IN RHESUS MONKEYS

NOVEL RECOMBINANT ADENOVIRUS VACCINE VECTORS FOR HIV/SIV IN RHESUS MONKEYS
用于恒河猴 HIV/SIV 的新型重组腺病毒疫苗载体
批准号：
7958318
负责人：
Dan H. Barouch
金额：
$11.19万
依托单位：
HARVARD MEDICAL SCHOOL
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
项目状态：
已结题
起止时间：
2009-05-01 至 2010-04-30
来源：
https://reporter.nih.gov/project-details/7958318
关键词：
AdenovirusesComputer Retrieval of Information on Scientific Projects DatabaseFrequenciesFundingGrantHIV-1 vaccineImmunityInstitutionMacaca mulattaNew EnglandPrimatesRecombinantsResearchResearch PersonnelResourcesSafetySerotypingSourceUnited States National Institutes of HealthVirusbaseimmunogenicitynovelvectorvector vaccinevector-based vaccine

项目摘要

项目成果

Dan H. Barouch的其他基金

相关文献

中文摘要
翻译
这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 对Ad5载体的高频率免疫已被证明抑制了免疫原性，并可能损害针对HIV-1的rAd5疫苗的安全性。为了克服这一障碍，我们开发了基于新型复制不能Rad载体的疫苗，这些疫苗来自罕见的Ad血清型和嵌合病毒。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The high frequency of pre-existing immunity to the Ad5 vector has been shown to suppress the immunogenicity and possibly impair the safety of rAd5 vaccines for HIV-1. To overcome this hurdle, we have developed novel replication-incompetent rAd vector-based vaccines derived from rare Ad serotypes and chimeric viruses.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NHP Core
Multi-Omics Analysis of Broadly Neutralizing Antibodies and Therapeutic Vaccination
Administrative Core
Multi-Omics Correlates of Broadly Neutralizing Antibody Efficacy